Analytical Data
-
基因名
RBL1
- Application
-
别名
107 kDa retinoblastoma-associated protein; Cellular protein 107; Cellular protein p107; CP107; MGC40006; p107; PRB1; RBL1; RBL1_HUMAN; Retinoblastoma like protein 1; retinoblastoma-like 1 (p107); Retinoblastoma-like protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P28749
-
表达区间
1-429 aa
-
氨基酸序列
MTAALAVVTTSGLEDGVPRSRGEGTGEVVLERGPGAAYHMFVVMEDLVEKLKLLRYEEEFLRKSNLKAPSRHYFALPTNPGEQFYMFCTLAAWLINKAGRPFEQPQEYDDPNATISNILSELRSFGRTADFPPSKLKSGYGEHVCYVLDCFAEEALKYIGFTWKRPIYPVEELEEESVAEDDAELTLNKVDEEFVEEETDNEENFIDLNVLKAQTYHLDMNETAKQEDILESTTDAAEWSLEVERVLPQLKVTIRTDNKDWRIHVDQMHQHRSGIESALKETKGFLDKLHNEITRTLEKISSREKYINNQLENLVQEYRAAQAQLSEAKERYQQGNGGVTERTRLLSEVMEELEKVKQEMEEKGSSMTDGAPLVKIKQSLTKLKQETVEMDIRIGIVEHTLLQSKLKEKSNMTRNMHATVIPEPATGFY
-
分子量
75.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RBL1, also known as Retinoblastoma-like protein 1, is a pivotal regulator of the cell cycle and a key player in tumor suppression. Its study is particularly significant in the context of cancer research, as mutations or dysregulation of RBL1 are implicated in various malignancies, including retinoblastoma and other types of tumors. The protein functions primarily by binding to E2F transcription factors, thereby inhibiting cell cycle progression from the G1 to the S phase, thus preventing uncontrolled cell proliferation. Recent studies have explored the use of recombinant RBL1 proteins to better understand their structure and function, aiming to elucidate the mechanisms behind its tumor-suppressive activity. Recombinant protein technology allows for the production of large quantities of pure RBL1, facilitating biochemical assays, crystallization studies, and functional analyses. These investigations are essential for developing potential therapeutic strategies that could reactivate or mimic RBL1 function in cancer cells where its activity is compromised. Furthermore, understanding the post-translational modifications and interactions of RBL1 might reveal novel pathways for targeted therapies. As such, research on recombinant RBL1 proteins is a promising frontier in the quest for innovative cancer treatments and enhancing our overall knowledge of cell cycle regulation.
